Histone deacetylases are validated targets for multiple therapeutic applications. Existing histone deacetylase inhibitors have a zinc chelating group, which limits their use due to metabolic instability.The presented work deals with exploration of novel binding sites in histone deacetylase 2 and 8 with photoreactive ligands for the design of histone deacetylase inhibitors without a zinc chelating group.